Japanese Pharmacopoeia (JP)

The Japanese Pharmacopoeia (JP) is Japan's official compendium of pharmaceutical standards. It establishes quality requirements, analytical procedures, specifications, monographs and general rules applicable to medicines, pharmaceutical substances and dosage forms covered by the Japanese system.

The JP is established by Japan's Ministry of Health, Labour and Welfare (MHLW), while the Pharmaceuticals and Medical Devices Agency (PMDA) contributes to the development and maintenance of pharmacopoeial standards. Its first edition was published in 1886, giving the Japanese Pharmacopoeia a long-established role in pharmaceutical quality control.

JP19: the 19th Edition of the Japanese Pharmacopoeia

The Japanese Pharmacopoeia 19th Edition, or JP19, came into effect on April 10, 2026. A transitional period allows previous standards to remain applicable under specified conditions until September 30, 2027, when implementation of the new standards is to be completed. ([pmda.go.jp][1])

The JP contains General Notices, rules for pharmaceutical preparations, General Tests, official monographs, reference spectra and general information. Compliance therefore may involve more than consulting an individual drug monograph; relevant general chapters and dosage-form requirements can also apply.

JP <4.01>: Bacterial Endotoxins Test

JP <4.01> Bacterial Endotoxins Test describes testing related to bacterial endotoxins. It is particularly relevant to parenteral products and other situations in which endotoxin control is required. The chapter is among the pharmacopoeial texts addressed through international harmonization activities. ([pmda.go.jp][2])

JP <4.06>: Sterility Test

JP <4.06> Sterility Test is one of the General Tests associated with microbiological quality control of products required to meet sterility specifications. It is also listed among JP general tests relevant to biological products.

JP <6.07>: Insoluble Particulate Matter Test for Injections

JP <6.07> Insoluble Particulate Matter Test for Injections addresses subvisible particulate contamination in injections and parenteral infusions. Analytical approaches associated with this test include Light Obscuration particle counting and microscopic particle counting when appropriate.

The JP19 revision is also significant for therapeutic protein products. Documents supporting the new edition show revision of <6.07> together with deletion of the former <6.17> chapter specifically dedicated to insoluble particulate matter in protein injections. ([pmda.go.jp][3])

JP <6.10>: Dissolution Test

JP <6.10> Dissolution Test is another important General Test. Dissolution testing evaluates release of an active substance from applicable pharmaceutical dosage forms under defined conditions. The chapter is among JP methods addressed through pharmacopoeial harmonization activities. ([pmda.go.jp][2])

Are the Japanese Pharmacopoeia, USP and European Pharmacopoeia identical?

No. The Japanese Pharmacopoeia, United States Pharmacopeia (USP) and European Pharmacopoeia (Ph. Eur.) are separate compendia. However, selected general chapters and monographs undergo international harmonization through the Pharmacopoeial Discussion Group (PDG). A harmonized chapter can still contain local or non-harmonized provisions, so equivalence should not be assumed for the entire pharmacopoeias.

Why is the Japanese Pharmacopoeia important in laboratories?

For pharmaceutical quality-control and analytical-development laboratories, the JP can define not only what must be tested but also the analytical principle, sample preparation, system suitability, acceptance requirements and other conditions relevant to a procedure. These requirements can influence method development, instrument qualification, laboratory workflows and interpretation of analytical results.

Frequently asked questions about the Japanese Pharmacopoeia

What does JP19 mean?

JP19 refers to the 19th Edition of the Japanese Pharmacopoeia, which came into effect on April 10, 2026. ([pmda.go.jp][1])

Does the Japanese Pharmacopoeia include particulate matter testing?

Yes. JP <6.07> addresses insoluble particulate matter in injections and includes approaches for subvisible particle evaluation, including Light Obscuration when applicable.

Are all JP methods harmonized with USP and Ph. Eur.?

No. Selected methods and monographs are harmonized through the PDG, but other provisions remain pharmacopoeia-specific. The current chapter and edition should always be checked for applicable requirements.